bioscrip inc focus provid home
altern site infus therapi via platform
reason report rate chang target price chang estim
chang analysi sales/earn
ew/vol pt
bio surpris market announc merger option
good kind surpris share slid
news one point close expect share
move higher week manag road sell
deal settl rang pf
posit view bio predic first clean
year plenti momentum year strategi
develop greenleaf drive growth attract home
infus industri stori chang attract element
combin entiti see materi sever
year ntm see mani catalyst concern
lever transform deal move equal-weight
volume target
estim revenu million y/i adj
ebitda million margin
estim revenu million y/i adj
ebitda million margin
step sidelin think friday reaction overdon
share settl rang particularli
manag team spend time larg sharehold
potenti sharehold appreci longer term merit
deal think could take year materi main issu
interim includ
major reason bio chang bio made signific
progress sinc greenleaf join compani
despit numer intern extern headwind thought
suppos year larg free restructuring/
reimburs distract saw path million adj
ebitda million possibl appear
pivot year could late assum close
view turnaround effect start smith
profit improv plan turnaround taken form
last coupl year becom jade wait anoth
coupl year also central thesi leadership
greenleaf expect remain special advisor
board option doubt integr
oper post-clos
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
lack clariti deal seem put togeth last minut believ result confer
call lack substanc sell longer term deal merit still good idea option
margin much lower bio core mix opportun improv margin
beyond cost synergi seem like million pf ebitda lowbal number base trough ttm
number realli clear us understand compani road next week
think merit becom better understood still hurri natur deal bio weak result creat
concern underli issu bio yet articul short think bio
option make deal
bewar transform deal understand option also turnaround phase put two
compani turnaround mode togeth lever balanc sheet seem like riski proposit us assum
cost synergi includ signific rif creat angst within employe base import asset
recruit like alreadi plan strategi poach talent worri signific cash restructur cost
well disrupt type combin mr greenleaf obvious plenti experi navig
issu note dubiou integr post-clos
reason optim upshot signific move equal-weight think investor
patienc longer term time horizon plenti upsid
largest pure-play home infus compani industri grow reason think
compani would grow faster industri bio note growth january/februari option
compound-annual-growth-rate
think sever hundr basi point margin improv state cost synergi well
continu improv core mix potenti revenu synergi believ million synergi
like underst given signific geograph overlap duplicit oper system
leverag profil move ebitda still high asset light compani
theyll much capac pay debt natur delver ebitda grow current
compani ebitda consum interest payment goe pf ebitda basi million
expect see signific de-lever futur think bio leverag profil singl largest
impedi investor address issu
industri could get relief rule calendar day issu nhia industri trade group file
lawsuit hh matter
investor want exposur home-bas care combin compani million year pf
ebitda estim enterpris valu billion billion ebitda open univers
potenti investor
valuat think bio effect forc deal believ million ebitda
target go unattain make address balanc sheet much challeng estim
adj ebitda combin compani million includ million year synergi
use multipl less discount averag home-bas care provid
think fair perhap gener compani still carri leverag visibl cloud
result stock
bio dilut heard grumbl bio ownership combin compani small
question rais confer call bio contribut million ebitda option
contribut million would bio ownership answer relat debt
make sens think look enterpris valu contribut better way look pf ownership also
think bio negoti posit strength given oner leverag major factor well
includ contribut cost synergi seemingli belong much option bio
proxi expect proxi file late april includ background deal discuss option
histor financi bios/opt financi project project interest see particularli
bio outlook suspect bio ebitda project much lower million still caution
reli heavili compani project think tend inflat compani make
case higher ownership percentag
structur bio issu new share option privat sharehold all-stock transact own
madison dearborn partner privat
combin compani deal expect complet second half transact
unanim approv board compani deal subject approv bio sharehold along
regulatori approv
leadership combin compani led option ceo john rademach option cfo mike
shapiro integr best talent process system compani bio presid ceo
greenleaf serv special advisor board director board consist director option
board two director bio carter pate david gold
pf leverag includ million synergi compani look balanc capit alloc strategi
includ de-lever also cash flow avail drive growth legaci bio ebitda
use debt servic compar pf compani
strateg merit deal compani highlight follow benefit transact includ
improv cost-effect patient care enhanc scale therapi offer expect growth
annual payor account net revenu combin compani cover us
popul importantli pf compani pure play independ home infus provid scale
aid manag care negoti ultim provid revenu synergi
merger model outlin merger model highlight key assumpt
assum revenu growth bio respect ebitda margin expand
result adj ebitda million million
well prior guidanc million adj ebitda expect run-rat ebitda million
result think could prove conserv though compani fell short million ebitda
target million adjust million bad debt
option assum revenu growth ebitda margin improv
assum million synergi realiz full million realiz result
adj ebitda million ebitda margin million ebitda margin
look assum bp annual margin expans thereaft
se next page project
 look like short realli know given deal bio give guidanc howev
confer call reveal littl outlook combin compani see home infus grow organ
rang profit grow faster revenu bio took million bad debt charg
could look past receiv littl detail around drive charg compani pf adj
ebitda million includ charg
overview result
thousand except per share
total revenu
sell gener administr expens
depreci amort
incom continu oper
pre-tax incom loss continu oper
net incom loss continu oper
accru dividend prefer stock
deem dividend prefer stock
net incom loss common
sell gener administr expens
compani report stephen inc
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
